JeffreyRInfanteMD

Clinical Trials

• CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas Start of enrollment: 2007 Nov 01

  Completed

  Phase 1, Phase 2

• A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) Start of enrollment: 2007 Dec 14

  Active, not recruiting

  Phase 1

• Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors Start of enrollment: 2008 Feb 01

  Completed

  Phase 1

• Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918 Start of enrollment: 2008 Aug 01

  Terminated

  Phase 1

• Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors Start of enrollment: 2008 Aug 01

  Completed

  Phase 1, Phase 2

• Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors Start of enrollment: 2010 Jul 01

  Completed

  Phase 1

• Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma Start of enrollment: 2010 Sep 28

  Completed

  Phase 1

• Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects Start of enrollment: 2011 Sep 01

  Completed

  Phase 1

• Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Start of enrollment: 2012 Jun 01

  Completed

  Phase 1, Phase 2

• A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors Start of enrollment: 2012 Nov 27

  Terminated

  Phase 1, Phase 2

• Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor Start of enrollment: 2012 Dec 01

  Completed

  Phase 1

• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12

  Completed

  Phase 3

• Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Start of enrollment: 2013 Mar 01

  Completed

  Phase 1, Phase 2

• LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma Start of enrollment: 2013 Nov 01

  Terminated

  Phase 2

• Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies Start of enrollment: 2013 Jun 01

  Terminated

  Phase 1

• Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Jul 01

  Terminated

  Phase 1

• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Start of enrollment: 2013 Nov 15

  Active, not recruiting

  Phase 1

• A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies Start of enrollment: 2013 Dec 19

  Completed

  Phase 1

• Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01

  Completed

  Phase 1

• A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 Start of enrollment: 2014 Apr 01

  Terminated

  Phase 1

• LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Start of enrollment: 2014 Jul 23

  Completed

  Phase 2

• A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors Start of enrollment: 2013 Nov 01

  Completed

  Phase 1

• ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Start of enrollment: 2014 Oct 01

  Completed

  Phase 1, Phase 2

• A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies Start of enrollment: 2016 Jun 17

  Completed

  Phase 1

• Join now to see all